Alexion Soars On Earnings Report

July 2007
BioWorld Today;7/26/2007, Vol. 18 Issue 144, p3
The article reveals the increase in the shares of Cheshire, Connecticut-based Alexion Pharmaceuticals Inc. after it released its second-quarter earnings, which showed a smaller than predicted loss. Alexion reported total revenues of $9.8 million, all from sales of recently launched Soliris, and a net loss of $27.2 million, or 75 cents per share. Soliris (eculizumab) is the first drug on the market to actually treat paroxysmal nocturnal hemoglobinuria and hit the market in April.


Related Articles

  • Alexion Pharmaceuticals. Investor's Business Daily // Investors Business Daily;4/13/2015, pA02 

    The article focuses on the approval given to Alexion Pharmaceuticals Inc. (ALXN) which will allow update of the label of its drug Soliris for paroxysmal nocturnal hemoglobinuria to include patients without history of transfusion.

  • Alexion Defies Biotech's Slow Sales Trend; Beats Estimates. Boggs, Jennifer // BioWorld Today;7/22/2011, Vol. 22 Issue 141, p1 

    The article reports on the second quarter earnings of Alexion Pharmaceuticals Inc. in 2011, which prompted the company to increase the sales guidance for its paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris. The price of the stocks of the company rose 9 percent on July 21, 2011 to close at...

  • Alexion Gets FDA Nod For Soliris; First Drug For PNH. Boggs, Jennifer // BioWorld Today;3/19/2007, Vol. 18 Issue 53, p1 

    The article reports that the monoclonal antibody product Soliris from Alexion Pharmaceuticals won U.S. Food and Drug Administration approval in paroxysmal nocturnal hemoglobinuria (PNH), making it the first therapy indicated for the rare genetic disorder. The news boosted the shares of Alexion...

  • Alexion, Others Show Resilience After Breakouts. KEN SHREVE // Investors Business Daily;12/3/2014, pB08 

    Stocks that show resilience and trade tightly after a are worth watching. Why? Because price action like this can often a new entry after an initial breakout.

  • EARNINGS ROUNDUP.  // BioWorld Today;10/27/2008, Vol. 19 Issue 209, p3 

    The article reports that Alexion Pharmaceuticals Inc. of Cheshire, Connecticut reported total revenue of $76.5 million for the third quarter of 2008. According to the article, this came from sales of paroxysmal nocturnal hemoglobinuria drug Soliris which were up from the $21.8 milion in revenues...

  • American Society of Hematology 2007.  // BioWorld Today;12/11/2007, Vol. 18 Issue 239, p3 

    The article reports on the open-label clinical study conducted by Alexion Pharmaceuticals Inc. According to the Cheshire, Connecticut-based company, paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder, was more likely for the general public to have than chronic kidney disease....

  • Advance Auto Parts, Boise Cascade Trade In A Tight Fashion. KEN HOOVER // Investors Business Daily;12/3/2014, pB03 

    The article offers information on the performance and trade of stocks of developer Alexion Pharmaceuticals, supplier Advance Auto Parts, and pulp and paper company Boise Cascade. Topics discussed include the quarterly earnings of Alexion, flat base of Advance Auto Parts' stock, and stock growth...

  • AbbVie Tops, Alexion Misses. Investor's Business Daily // Investors Business Daily;4/24/2015, pA01 


  • Celgene, Alexion EPS Beat. Investor's Business Daily // Investors Business Daily;10/25/2013, pA01 



Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics